AlphaRx to Present at the 6th International Drug Delivery Technologies & Deal-Making Summit.Business Editors, Health/Medical Writers BIOWIRE2K RICHMOND HILL, Ontario--(BW HealthWire)--May 29, 2001 AlphaRx Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :AHRX) announced today that it will undertake a presentation of the company's technology at the 6th International Drug Delivery Technologies & Deal-Making Summit on July 26, 2001. This annual meeting is attended by over two hundred and fifty scientists, business development, licensing, executive management, and investment professionals. The Company will present a paper highlighting the effectiveness of its novel Self Emulsifying Controlled Release Tablet (S.E.C.R.E.T.) system for oral delivery of poorly water-soluble drugs. The scientific paper will discuss the Company's S.E.C.R.E.T. System which improves the bioavailability bioavailability /bio·avail·a·bil·i·ty/ (bi?o-ah-val?ah-bil´i-te) the degree to which a drug or other substance becomes available to the target tissue after administration. bi·o·a·vail·a·bil·i·ty n. and bioperformance of hydrophobic hydrophobic /hy·dro·pho·bic/ (-fo´bik) 1. pertaining to hydrophobia (rabies). 2. not readily absorbing water, or being adversely affected by water. 3. and lipophilic lipophilic, adj/n the ability to dissolve or attach to lipids. lipophilic (lipōfil´ik), adj 1. showing a marked attraction to, or solubility in, lipids. 2. drugs. Emphasis will be placed on the fact that S.E.C.R.E.T. tablet fabrication fabrication (fab´rikā´sh  n),n the construction or making of a restoration. uses traditional pharmaceutical methods and standard manufacturing equipment. This cannot be accomplished with traditional oil-in-water systems such as soft and hard gelatin gelatin or animal jelly, foodstuff obtained from connective tissue (found in hoofs, bones, tendons, ligaments, and cartilage) of vertebrate animals by the action of boiling water or dilute acid. capsules, which substantially increase fabrication costs. The presentation will highlight the system's significant versatility and flexibility in dosage formulation for immediate or controlled release of complex lipophilic drug molecules. "Resolution of formulation problems is a vital hurdle to be overcome in the development of new drugs. With a large number of new chemical entities exhibiting poor water solubility and resultant complex technical formulation problems, AlphaRx's S.E.C.R.E.T. system can be cost-effectively applied to the oral delivery of many of these lipophilic drug molecules," said Mr. Michael Lee, President of AlphaRx. "We are very pleased to be invited to present AlphaRx's superior drug technology in a forum that showcases world class drug companies such as GlaxoSmithKline, Eli Lilly and Pfizer, among others. The three day deal-making conference will enable us to effectively introduce AlphaRx's exciting story to a diverse group of investors and, at the same time, provide licensing opportunities with other pharmaceutical companies," Mr. Lee added. "Deal-Makers says it all." For additional about AlphaRx, please visit our website at www.AlphaRx.com FORWARD LOOKING STATEMENTS: This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions of the Securities Litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion